Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
Ruxolitinib was found to be more cost-effective than the best available therapy (BAT) when the willingness-to-pay threshold for payers was at $150,000 and applied to patients with hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly, according to a new study.
Read More
Sociodemographic Factors Influence Outcomes Among Patients With Psoriasis
May 22nd 2020A patient’s sex, disease duration, and residence were the most common sociodemographic factors shown to affect illness acceptance, life satisfaction, sense of stigmatization, and quality of life among those who have psoriasis, according to the results of a recent study.
Read More
Pharmacies Adapt in the Wake of Challenges Created by COVID-19, Panel Says
May 15th 2020In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.
Read More
Platelet Abnormalities Play Role in CVD in Patients With Psoriasis, Report Says
May 15th 2020Platelet function may aid in determining disease severity for patients with psoriasis who are at an increased risk of developing cardiovascular disease (CVD) and increased inflammation, a review notes.
Read More
Expanding Use of Biosimilar Pegfilgrastim Could Save Millions, Study Says
May 10th 2020Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.
Read More
Psoriasis Guidelines From AAD, NPF Spotlight Comorbidities
May 8th 2020Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.
Read More
FDA Approves Orphan Drug Pemigatinib for Rare Bile Duct Cancer Cholangiocarcinoma
April 20th 2020The FDA Friday approved pemigatinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Read More
Socioeconomic, Personality Factors Found to Impact Quality of Life for Patients With Facial Palsy
April 19th 2020Researchers found that the factors most associated with health related quality of life (HRQOL) in patients with facial palsy are age, bilateral facial palsy, severity of facial palsy, anxiety, and key personality traits, including extraversion and emotional stability.
Read More
FDA, FTC Need to Strengthen Biosimilar Efforts, AHIP Says
April 18th 2020AHIP wants the FDA and FTC to streamline product approvals, clarify the regulations governing biosimilars, put a stop to attempts to discourage people from using biosimilars, and start educating providers and patients about the safety and efficacy of these products.
Read More
FDA Issues Guidance for Developers Targeting Therapies for Single Enzyme Defect Diseases
April 12th 2020The FDA released guidance on what sponsors should take into account when trying to demonstrate clinical effectiveness of new treatments in patients with slowly progressive, low-prevalence rare diseases with substrate deposition that result from single enzyme defects.
Read More
Study: Inconsistency of Rare Disease Definitions Causes Problems That Standardization Could Fix
February 19th 2020Investigators say that inconsistencies in the way rare diseases are defined contribute to misdiagnoses, delayed treatment, and other ills that could be addressed with global standards.
Read More